Loading clinical trials...
Loading clinical trials...
Phase III, Multicenter, Randomized, Simple-blinded, Parallel Groups to Evaluate Non Inferiority of Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Persistent Rhinitis Moderate to Severe
This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.
Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the intention to collect more data about safety and efficacy and present them to local authority. This study was draw to treat patients with persistent rhinitis moderate to severe in sites located locally in Brazil.
Age
12 - 90 years
Sex
ALL
Healthy Volunteers
No
Alexandra Dumont
Campinas, Brazil
Start Date
October 8, 2019
Primary Completion Date
October 8, 2019
Completion Date
October 8, 2019
Last Updated
October 9, 2019
Budesonid 50mcg (Noex)
DRUG
Budesonid 50mcg (Busonid)
DRUG
Lead Sponsor
Eurofarma Laboratorios S.A.
NCT00779545
NCT00406783
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00988247